Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin and Metronidazole Suppositories for Chronic Endometritis
NCT06650540Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of levofloxacin and metronidazole in endometritis (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Live birth rate after the first embryo transfer. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
levofloxacinmetronidazole
03
Conditions
endometritis
Beyond the preview
Go deeper on NCT06650540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650540.